Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

How much could Operation Warp Speed change pharma, medtech distribution?

By Chris Newmarker | October 7, 2020

Operation Warp Speed COVID-19 vaccine

[Photo by Stefan Cosma on Unsplash]

A top U.S. Department of Health and Human Services official used an appearance today at a virtual medtech conference to repeat the U.S. government’s astounding goal for its Operation Warp Speed program: start delivering 300 million doses of a safe, effective COVID-19 vaccine by January 2021.

The project could revolutionize not only how pharmaceuticals are distributed, but also medical devices and ancillary supplies, HHS Assistant Secretary Dr. Robert Kadlec claimed during The Virtual Medtech Conference hosted by AdvaMed.

The Centers for Disease Control and Prevention with U.S. Defense Department support is collaborating with the private sector — as well as state and local authorities — to meet Operation Warp speed goals, Kadlec said. Top private sector partners include McKesson, which has a COVID-19 vaccine distribution agreement with HHS and DoD, as well as providers of ancillary supplies such as Becton Dickinson (NYSE:BDX).

“When a dose of vaccine is approved by the FDA, no corner is cut, no shortcut is taken. We can basically deploy that vaccine and begin administering it in 24 hours. That is an extraordinary target and goal that Warp Speed has,” Kadlec said.

As HHS explained while releasing distribution strategy documents in September, McKesson will work under CDC’s guidance, with logistical support from DoD, to ship COVID-19 vaccines to administration sites.

The vaccine distribution will go through three phases, according to the strategy documents. The distribution will start in a focused manner, with the goal of maximizing vaccine acceptance and public health protection while minimizing waste and inefficiency. As more vaccine doses become available, distribution will expand to the wider population. Americans will receive the government-purchased vaccines at no cost.

Top experts inside the government — including Dr. Anthony Fauci of the National Institute of Allergy and Infectious Diseases and Dr. Robert Redfield of the CDC — have said the U.S. could be months into 2021 before a COVID-19 vaccine is widely available.

For now, the federal government is making investments in the necessary manufacturing capacity at its own risk — even as a handful of vaccine candidates remain in Phase 3 clinical trials. FDA told COVID-19 vaccine developers yesterday that it needs two months’ worth of safety data before it will consider emergency approvals — defying calls from President Donald Trump to hurry up the vaccine approval process.

 

 

About The Author

Chris Newmarker

Chris Newmarker is the executive editor of WTWH Media life science's news websites and publications including MassDevice, Medical Design & Outsourcing and more. A professional journalist of 18 years, he is a veteran of UBM (now Informa) and The Associated Press whose career has taken him from Ohio to Virginia, New Jersey and, most recently, Minnesota. He’s covered a wide variety of subjects, but his focus over the past decade has been business and technology. He holds bachelor’s degrees in journalism and political science from Ohio State University. Connect with him on LinkedIn or email at cnewmarker@wtwhmedia.com.

Tell Us What You Think! Cancel reply

Related Articles Read More >

Sandoz Logo 2025
Sandoz breaks ground on biosimilar plant in Slovenia
Nymi Logo_2022 (1)
Nymi, Caliber partner on passwordless authentication for pharma manufacturing
Building a resilient pharma supply chain
Antheia_Logo (1)
Pharma ingredient manufacturer Antheia raises $56M Series C
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE